Genetic Disorders
When errors in DNA sequence or chromosome number cause non-infectious disease — from conception onwards
Download this lesson's worksheet
Use the PDF for classwork, homework or revision. It includes key ideas, activities, questions, an extend task and success-criteria proof.
Before you read
Consider this claim: "CRISPR-Cas9 can now cure any genetic disease — if we can read the genome, we can fix it."
Write down what you know about genetic disorders and gene-editing technologies. Do you think this claim is accurate or an oversimplification? What would need to be true for it to be correct?
Know
- Types of genetic disorders: chromosomal abnormalities and single-gene (Mendelian) disorders
- Examples: Down syndrome, Turner, Klinefelter, CF, PKU, Huntington's, haemophilia
- Diagnostic tools: karyotyping, NIPT, amniocentesis, newborn screening
Understand
- How non-disjunction produces chromosomal abnormalities
- How mutations affect protein function and cause single-gene disorders
- How inheritance patterns (AR, AD, X-linked) predict disease risk
- The difference between screening and diagnostic tests
Can Do
- Classify a genetic disorder by type and inheritance pattern
- Evaluate the benefits, limitations and ethics of genetic diagnosis
- Assess gene therapy and CRISPR as prevention strategies
What Is a Genetic Disorder?
Classification, causes and population burden
A genetic disorder arises from a heritable error in the DNA — either in the number or arrangement of entire chromosomes, or within the sequence of a single gene. Unlike environmental or nutritional diseases, the cause is written into the genome from the earliest stages of development.
Genetic disorders are classified into three main categories:
- Chromosomal disorders — abnormal chromosome number (aneuploidy) or structure (translocation, deletion, duplication). Examples: Down syndrome, Turner syndrome, Klinefelter syndrome.
- Single-gene (Mendelian) disorders — mutation in one gene disrupts normal protein function; follow predictable inheritance patterns. Examples: cystic fibrosis, Huntington's disease, haemophilia A.
- Multifactorial (polygenic and environmental) disorders — result from the interaction of multiple gene variants with environmental factors. Examples: Type 2 diabetes, heart disease, schizophrenia. These are harder to predict and do not follow simple Mendelian ratios.
This lesson focuses on chromosomal and single-gene disorders, as these have the clearest cause-and-effect pathways and the most direct diagnostic implications.
Inherited vs De Novo Mutations
Not all genetic disorders are inherited from a parent. De novo mutations arise spontaneously during gamete formation or early embryonic development and are not present in either parent. The majority of chromosomal abnormalities are de novo (caused by non-disjunction). Many single-gene disorders can be either inherited or de novo.
Chromosomal Abnormalities
Non-disjunction, trisomy, monosomy and translocation
Chromosomal abnormalities arise when gametes carry the wrong chromosome number — most often because homologous chromosomes fail to separate during meiosis. The fertilised egg then begins life with cells containing too many or too few chromosomes.
Non-Disjunction: The Core Mechanism
During meiosis I or meiosis II, chromosomes normally separate equally into daughter cells. Non-disjunction occurs when chromosomes fail to separate, producing one gamete with two copies of a chromosome and another with none.
Major Chromosomal Disorders
| Condition | Chromosome change | Karyotype | Key features | Frequency |
|---|---|---|---|---|
| Down syndrome | Trisomy 21 (extra chromosome 21) | 47, +21 | Intellectual disability (variable), characteristic facial features, heart defects, increased Alzheimer risk in adulthood | ~1 in 700 live births; rises steeply with maternal age |
| Edwards syndrome | Trisomy 18 | 47, +18 | Severe intellectual disability, heart/kidney malformations; most pregnancies end in miscarriage; median survival months | ~1 in 5,000 live births |
| Turner syndrome | Monosomy X (one X, no second sex chromosome) | 45, X0 (females only) | Short stature, infertility (streak ovaries), heart defects; normal intelligence; treated with oestrogen replacement | ~1 in 2,000 females |
| Klinefelter syndrome | Trisomy — extra X in males | 47, XXY (males only) | Taller stature, infertility (small testes, low testosterone), mild learning difficulties; often undiagnosed until adulthood | ~1 in 650 males |
Structural Chromosomal Abnormalities
Chromosomal disorders can also arise from structural rearrangements rather than number changes:
- Translocation — a segment of one chromosome breaks off and attaches to another. In familial Down syndrome, part of chromosome 21 is translocated onto chromosome 14; the individual has 46 chromosomes but 3 functional copies of chromosome 21. This can be inherited from a carrier parent.
- Deletion — loss of a chromosome segment (e.g. Cri-du-chat syndrome: deletion of part of chromosome 5).
- Duplication — a segment is copied twice, leading to overexpression of genes in that region.
The three major chromosomal disorders caused by nondisjunction, with karyotype notation, key features and population frequency.
Single-Gene Disorders and Inheritance Patterns
How one faulty gene can cause disease — and how it is passed on
Single-gene disorders follow the inheritance rules established by Mendel. The pattern of transmission — who is affected, which generations, which sexes — depends entirely on whether the allele is dominant or recessive, and whether it is carried on an autosome or a sex chromosome.
Autosomal Recessive (AR)
Both copies of the gene must be defective. Parents are often unaffected carriers (Aa). Each pregnancy of two carriers: 25% affected.
- Cystic Fibrosis (CFTR gene)
- PKU (PAH gene)
- Tay-Sachs (HEXA gene)
- Sickle-cell disease (HBB gene)
Autosomal Dominant (AD)
One faulty copy is sufficient. Affected individuals usually have one affected parent. Each pregnancy: 50% affected.
- Huntington's disease (HTT gene)
- Marfan syndrome (FBN1 gene)
- Neurofibromatosis type 1
- Familial hypercholesterolaemia
X-linked Recessive (XLR)
Gene is on X chromosome. Females with one copy are carriers (unaffected). Males with one copy are affected (only one X).
- Haemophilia A (F8 gene)
- Duchenne muscular dystrophy (DMD gene)
- Colour blindness (OPN1LW/OPN1MW genes)
Mitochondrial
Mutations in mitochondrial DNA. Inherited exclusively from the mother (mitochondria in egg, not sperm). All children of an affected mother are at risk.
- Leber hereditary optic neuropathy
- MELAS syndrome
Mechanism: Cystic Fibrosis (CF)
CF is caused by mutations in the CFTR gene on chromosome 7. CFTR encodes a chloride channel protein in the epithelial cell membrane. The most common mutation, delta-F508, causes the CFTR protein to misfold and be destroyed before reaching the cell surface.
Without functional CFTR, chloride ions cannot exit cells. Water follows chloride by osmosis — without water movement, mucus in the lungs, pancreatic ducts, and reproductive tract becomes abnormally thick. Consequences include chronic lung infections, pancreatic enzyme deficiency (malabsorption), and infertility in males.
Mechanism: Huntington's Disease (HD)
HD is caused by an expanded CAG trinucleotide repeat in the HTT gene on chromosome 4. Normal individuals have up to 35 CAG repeats; individuals with HD have 36 or more. The extra-long polyglutamine tract in the huntingtin protein causes it to misfold and aggregate in neurons, particularly in the striatum of the basal ganglia.
HD is autosomal dominant with virtually 100% penetrance — every individual who inherits the expanded allele will develop the disease if they live long enough (onset typically 30–50 years). HD shows anticipation: the repeat region tends to expand further in successive generations, causing earlier onset and more severe disease in children of affected individuals.
The genetic testing timeline from preconception carrier screening through newborn screening, plus the critical distinction between screening and diagnostic tests.
Genetic Diagnosis and Screening
Karyotyping, NIPT, amniocentesis and newborn screening programs
Identifying genetic disorders early — before symptoms appear, during pregnancy, or at birth — gives patients, families and clinicians the ability to make informed decisions about management. It is critical to distinguish between screening (risk assessment of a population) and diagnosis (definitive confirmation in an individual).
| Test | Type | How it works | Timing | Risk / Limitations |
|---|---|---|---|---|
| Karyotyping | Diagnostic | Cells cultured, chromosomes stained and photographed at metaphase; arranged by size and banding pattern to detect aneuploidy or structural changes | Postnatal (blood), or prenatal after invasive sampling | Cannot detect single-gene mutations; limited resolution for small deletions |
| NIPT | Screening | Analyses cell-free fetal DNA (cfDNA) shed into maternal blood; detects over- or under-representation of chromosomal DNA sequences | From 10 weeks gestation | Screening only — positive result requires diagnostic confirmation; twin pregnancies complicate interpretation; does not detect all abnormalities |
| Amniocentesis | Diagnostic | Needle inserted through abdomen into amniotic fluid (15–20 weeks); fetal cells grown and karyotyped or tested for specific gene mutations by PCR/DNA sequencing | 15–20 weeks gestation | ~0.5% miscarriage risk; cannot be done early; results take 2–4 weeks (culture) or days (FISH) |
| CVS (chorionic villus sampling) | Diagnostic | Small amount of placental tissue taken 10–13 weeks; earlier result than amniocentesis | 10–13 weeks gestation | ~1% miscarriage risk; cannot detect neural tube defects; slightly higher risk than amniocentesis |
| Newborn screening (Guthrie card) | Screening | Dried blood spot collected from heel at 48–72 hours; screened for metabolic and endocrine disorders (PKU, congenital hypothyroidism, galactosaemia, CF) | 48–72 hours after birth | Universal in Australia; false positives possible; does not detect chromosomal disorders |
| Carrier testing | Diagnostic | DNA test for adults with family history of AR or XLR conditions; identifies heterozygous carriers of CF, fragile X, spinal muscular atrophy | Any time — ideally before pregnancy | Does not confirm disease; psychological impact; may affect insurance eligibility |
Green rows = lower procedural risk. Red-tinted rows = invasive procedures with miscarriage risk.
Preimplantation Genetic Testing (PGT)
For couples at high risk of passing on a serious genetic disorder (e.g. both carriers of CF), IVF can be combined with preimplantation genetic testing. One or two cells are removed from a day-5 blastocyst and tested by PCR or chromosomal microarray. Only unaffected embryos are transferred to the uterus. PGT avoids the ethical difficulty of terminating an established pregnancy, but IVF is invasive, costly, and not always successful.
Prevention, Treatment and Ethical Considerations
Gene therapy, CRISPR and the limits of genetic intervention
Most genetic disorders cannot currently be cured — management aims to treat symptoms and compensate for defective protein function. Gene therapy offers the prospect of addressing the root cause, but its clinical application remains limited and raises significant ethical questions.
Current Management Strategies
- Symptomatic treatment — physiotherapy and DNase inhalation for CF lung disease; insulin for Type 1 diabetes; clotting factor infusions for haemophilia
- Dietary modification — phenylalanine-restricted diet for PKU prevents neurological damage; galactose-free diet for galactosaemia
- CFTR modulators (targeted therapy) — drugs such as ivacaftor, tezacaftor and elexacaftor directly improve CFTR protein function in patients with specific mutations (e.g. delta-F508 homozygotes). A major advance, but not applicable to all CF mutations.
- Hormone replacement — oestrogen for Turner syndrome; growth hormone for short stature disorders
Gene Therapy
Gene therapy delivers a functional copy of a defective gene into patient cells. The two main delivery systems are:
- Viral vectors — modified adeno-associated viruses (AAV) or lentiviruses carry the therapeutic gene into cells. Approved therapies include Luxturna (RPE65 mutation causing blindness) and Zolgensma (spinal muscular atrophy).
- CRISPR-Cas9 — molecular scissors that can cut DNA at a precise location guided by a short RNA sequence, then either disrupt a gene or template-guide repair to correct a mutation. Approved in 2023 for sickle-cell disease and beta-thalassaemia (Casgevy — the first CRISPR therapy approved globally).
Ethical Considerations in Genetic Medicine
Casgevy: The First Approved CRISPR Therapy (2023)
In November 2023, the US FDA approved Casgevy (exa-cel), developed by Vertex Pharmaceuticals and CRISPR Therapeutics, for sickle-cell disease and beta-thalassaemia. It works by reactivating fetal haemoglobin production in the patient's own stem cells using CRISPR-Cas9 — effectively providing a functional replacement for defective adult haemoglobin.
Cost: approximately AUD $3.5 million per patient for a single treatment. This raises the fundamental question explored in IQ4: even when prevention or cure is technically possible, how do societies decide who can access it?
Common Misconceptions
Misconception: "If a disease is genetic, you will definitely get it." Correction: Penetrance varies. BRCA1 breast cancer risk is high (~70%) but not 100%. Genetic means increased risk or certainty only if penetrance is 100% (as in Huntington's with large CAG repeats). For most genetic conditions, environment, lifestyle, and modifier genes influence whether and how severely the condition manifests.
Misconception: "CRISPR can currently cure any genetic disease." Correction: As of 2024, CRISPR therapy has been approved for only two conditions (sickle-cell disease and beta-thalassaemia). Delivery to organs other than the blood, off-target editing risks, and cost remain major obstacles. Stating that CRISPR is a 'current widespread prevention method' is factually incorrect in an HSC context.
Misconception: "Chromosomal abnormalities are always inherited from a parent." Correction: The vast majority of trisomies (e.g. trisomy 21) are de novo — arising from non-disjunction in the parent's gametes. The parent has a normal karyotype. Only translocation-type Down syndrome can be familially inherited from a carrier parent with 45 chromosomes (who is phenotypically normal but carries a translocated chromosome 21).
Misconception: "Carriers of recessive conditions are partially affected." Correction: Carriers of autosomal recessive conditions (e.g. CF carriers, sickle-cell trait) are almost always phenotypically normal. Their one functional allele produces enough protein to compensate. This is a critical distinction: heterozygous carriers are unaffected; only homozygous recessive individuals (or compound heterozygotes) develop the disease.
Copy into your books
▼Chromosomal Disorders
- Cause: non-disjunction during meiosis
- Trisomy 21 (Down): 47,+21; intellectual disability, heart defects
- Turner (45,X0): monosomy X; female, infertile, short stature
- Klinefelter (47,XXY): extra X in males; infertile, tall
- Translocation: 46 chromosomes but 3 copies of chromosome 21 function — familial Down
Single-Gene Disorders
- AR: CF (CFTR), PKU (PAH) — both copies mutated, parents carriers
- AD: Huntington's (HTT, CAG repeat), Marfan — one copy sufficient
- XLR: Haemophilia A (F8), DMD — males affected, females carriers
- HD: 100% penetrance, anticipation (repeat expands each generation)
Genetic Diagnosis
- Karyotype: chromosome number/structure; not single genes
- NIPT: cfDNA in maternal blood; screen only (10 weeks+)
- Amniocentesis: amniotic fluid; diagnostic; 0.5% miscarriage risk (15–20 wk)
- CVS: placental tissue; earlier (10–13 wk); 1% miscarriage risk
- Newborn screening (Guthrie card): PKU, CF, hypothyroidism at 48 h
Prevention and Ethics
- Gene therapy: viral vectors deliver functional gene (Luxturna, Zolgensma)
- CRISPR: approved 2023 for sickle-cell/thalassaemia (Casgevy)
- Somatic editing: individual only; germline: heritable (banned most countries)
- Ethics: access equity, genetic discrimination, reproductive autonomy, off-target effects
Try this: Analyse the pedigree and predict the inheritance pattern for each family. Use the Punnett square tool to verify your prediction.
This predictor trains you to recognise autosomal dominant, autosomal recessive, and X-linked patterns from pedigree diagrams.
Autosomal dominant traits appear in every generation and affect both sexes equally. Autosomal recessive traits skip generations and require two copies of the mutant allele. X-linked traits show sex-specific patterns, with males more frequently affected. Pedigree analysis is a core HSC skill.
Try this: Read each pedigree description and classify the inheritance pattern. Justify your answer using evidence from the family tree.
This classifier reinforces the diagnostic criteria for each inheritance pattern.
Key pedigree clues: affected individuals in every generation → dominant; unaffected parents with affected offspring → recessive; more affected males with no male-to-male transmission → X-linked. Always justify your classification with specific pedigree evidence.
Inheritance Pattern Detective
For each genetic disorder below, classify its inheritance pattern and complete the table. Then answer the questions that follow.
Cystic fibrosis
Huntington's disease
Haemophilia A
Down syndrome (trisomy 21)
PKU
APedigree interpretation: In a family, a mother is an unaffected carrier of haemophilia A and the father is unaffected. What are the probabilities that (i) a son is affected; (ii) a daughter is a carrier? Show your working using a Punnett square.
BRisk calculation: Both of Priya's parents are carriers of cystic fibrosis but are unaffected themselves. Priya is unaffected. What is the probability that Priya is a carrier? (Hint: consider all possible unaffected genotypes.)
Evaluating Gene Therapy as a Prevention Strategy
Use the scenario and the information from this lesson to answer the questions below.
1Explain why DMD predominantly affects males. Include a diagram of the inheritance pattern.
2Describe two benefits and two limitations of using CRISPR-Cas9 to treat DMD. Use specific biological evidence.
3A family asks whether the CRISPR therapy could be used during IVF to prevent their child from inheriting DMD entirely (germline editing). Evaluate the scientific and ethical implications of this approach compared to preimplantation genetic testing (PGT).
Multiple Choice
1. Down syndrome is most commonly caused by:
2. A male with haemophilia A (X-linked recessive) has children with a female who is a carrier. What is the probability that their daughter will be affected?
3. Which of the following best describes a screening test in the context of genetic diagnosis?
4. Huntington's disease demonstrates 'anticipation'. This means that:
5. A new gene therapy using CRISPR-Cas9 corrects a mutation in a patient's blood stem cells. The children of this patient will:
Short Answer Questions
Question 1. Explain how non-disjunction during meiosis can result in Turner syndrome. In your answer, describe the chromosome abnormality present and outline two clinical features of the condition. 4 marks
Question 2. Compare the usefulness of NIPT (non-invasive prenatal testing) and amniocentesis as methods of detecting chromosomal abnormalities during pregnancy. In your answer, refer to: the type of test (screening vs. diagnostic), procedural risk, timing, and information provided. 5 marks
Question 3. Evaluate the statement: "Advances in genetic technology mean that genetic disorders will soon be entirely preventable." In your response, discuss gene therapy (including CRISPR), preimplantation genetic testing, and genetic screening programs. Consider both the scientific and ethical dimensions. 6 marks
Revisit Your Thinking
At the start of this lesson, you evaluated the claim that "CRISPR-Cas9 can now cure any genetic disease." Return to what you wrote and consider:
- CRISPR-Cas9 was approved for its first clinical use (sickle-cell disease) in 2023 — but only for one type of disorder affecting accessible cells in the blood. Applying it to other organs, to chromosomal disorders, or to multifactorial diseases faces entirely different challenges.
- The claim is an oversimplification. Gene therapy is a rapidly advancing field, but delivery, off-target effects, cost, and the distinction between somatic and germline editing all limit its current scope.
- Prevention of genetic disorders also involves screening programs (newborn, prenatal, carrier testing) and PGT — technologies that are more widely available now than gene therapy.
How has your understanding of both the potential and the limits of genetic technology changed?
Model Answers
▼MC Answers: 1-B 2-B 3-C 4-D 5-A
Activity 1A — Haemophilia Punnett Square
Mother: XHXh (carrier). Father: XHY (unaffected). Cross gives: XHXH (normal daughter), XHXh (carrier daughter), XHY (normal son), XhY (affected son). (i) Probability a son is affected = 1/2 (50%). (ii) Probability a daughter is a carrier = 1/2 (50%).
Activity 1B — Carrier Probability for Priya
Both parents are carriers (Aa). Possible unaffected offspring: AA (1/4) and Aa (2/4). Of the 3/4 unaffected offspring, 2/4 are carriers. Therefore the probability that Priya (unaffected) is a carrier = 2/3 (approximately 67%).
Short Answer 1 — Turner Syndrome (4 marks)
Non-disjunction occurs when sex chromosomes fail to separate during meiosis I or II in one parent (usually the mother). This produces an egg containing no X chromosome. When fertilised by a Y-bearing sperm, the result is a 45,Y zygote (lethal). When fertilised by an X-bearing sperm, the result is a 45,X0 zygote — Turner syndrome. (1 mark for mechanism; 1 mark for karyotype 45,X0.)
Two clinical features (1 mark each, any two of): short stature due to haploinsufficiency of the SHOX gene on the X chromosome; gonadal dysgenesis (streak ovaries) leading to infertility and lack of pubertal development without oestrogen treatment; coarctation of the aorta (heart defect); lymphoedema of the hands and feet at birth; webbed neck.
Short Answer 2 — NIPT vs Amniocentesis (5 marks)
NIPT: A screening test — identifies risk, does not diagnose. Analyses cell-free fetal DNA in maternal blood. Performed from 10 weeks gestation. No procedural miscarriage risk. Highly sensitive for trisomies 21, 18, 13 but positive result requires confirmation. Does not detect single-gene disorders or structural abnormalities unless specifically targeted. (2 marks)
Amniocentesis: A diagnostic test — provides definitive cytogenetic or molecular diagnosis. Sample of amniotic fluid contains fetal cells; cells are cultured for karyotyping or analysed by PCR/sequencing for specific mutations. Performed at 15–20 weeks. Carries ~0.5% miscarriage risk. Can detect chromosomal abnormalities AND single-gene disorders. Results take 2–14 days depending on method. (2 marks)
Comparison: NIPT should be used first (low risk, early) to identify at-risk pregnancies; amniocentesis is offered when NIPT is positive or when older maternal age / family history makes diagnostic certainty important. The choice involves trade-offs between risk, certainty and timing. (1 mark)
Short Answer 3 — Extended Response Model (6 marks)
Judgement: The statement is an oversimplification. Genetic disorders will not be "entirely" preventable in the near future. Significant progress is being made, but scientific, practical, and ethical barriers remain substantial.
Gene therapy and CRISPR (2 marks): CRISPR-based therapy (Casgevy) was approved in 2023 for sickle-cell disease and beta-thalassaemia — a genuine breakthrough. However, current somatic gene therapy does not prevent inheritance of the disease allele in future generations. Germline editing would be heritable but is banned in most countries due to risks of off-target editing and long-term unknown consequences. Delivery to organs such as muscle, brain or lung remains a major challenge. Cost (~$3M per patient) limits access globally. Therefore, CRISPR is not currently a population-level prevention strategy.
PGT and prenatal screening (2 marks): Preimplantation genetic testing allows unaffected IVF embryos to be selected — effective prevention for families at known risk of serious single-gene disorders, but requires IVF (invasive, costly, not universally successful). NIPT and amniocentesis enable prenatal detection — but prevention depends on the decision to terminate a pregnancy, which involves profound ethical and personal choices. These technologies are available to high-income populations but not equitably accessible globally.
Scientific and ethical evaluation (2 marks): Chromosomal disorders arising from de novo non-disjunction cannot be prevented by gene therapy — they require prenatal diagnosis or embryo selection. Multifactorial disorders (most of the disease burden) are not addressable by single-gene approaches. Ethical issues include: reproductive autonomy (who decides which embryos are selected?), genetic discrimination, the risk of eugenics, and the tension between preventing suffering and respecting the dignity of those living with genetic conditions. A balanced conclusion: prevention is increasingly possible for specific single-gene disorders, but "entirely preventable" ignores the complexity of multifactorial disease, equity barriers, and fundamental ethical limits.
Boss Battle — Genetic Disorders Final!
The ultimate Module 8 challenge — use all your knowledge of genetic disorders to defeat the final boss. Pool: lessons 1–17.
Mark lesson as complete
Lesson 17 of 21 — Genetic Disorders